Given THBA’s natural occurrence in food and its very favorable risk-benefit profile, Glycemicon will develop its first product THBA as a nutraceutical.
Because of the lack of efficacious and safe products for the management of prediabetes, prediabetic people represent a highly interesting target group for THBA. Due to the mode of action of THBA and its excellent safety profile, THBA might also be interesting for juveniles with prediabetes or early stage diabetes.
For diabetic patients, we envision a nutraceutical product to be co-administered with current anti-diabetic drugs.
In addition to human use, the active compound THBA represents a very promising way to manage type 2 diabetes in pets, in particular in cats.
For more information about partnering with Glycemicon please email email@example.com